1 – 100 of 393
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice
(
- Contribution to journal › Article
- 2023
-
Mark
Gut hormone-based pharmacology : novel formulations and future possibilities for metabolic disease therapy
(
- Contribution to journal › Scientific review
-
Mark
Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
(
- Contribution to journal › Article
-
Mark
Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients
(
- Contribution to journal › Article
-
Mark
Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion : The human literature revisited and a systematic study in model experiments in mice
(
- Contribution to journal › Article
-
Mark
The Glucose Sensitivity of Insulin Secretion-Lessons from In Vivo and In Vitro Studies in Mice
(
- Contribution to journal › Article
-
Mark
Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function : Review on Mathematical Modelling Approaches
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice
(
- Contribution to journal › Article
-
Mark
The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
(
- Contribution to journal › Article
-
Mark
Glucose effectiveness : Lessons from studies on insulin-independent glucose clearance in mice
(
- Contribution to journal › Scientific review
-
Mark
Hepatic and extrahepatic insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors
(
- Contribution to journal › Article
-
Mark
Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice
(
- Contribution to journal › Article
-
Mark
The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice : Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice
(
- Contribution to journal › Article
-
Mark
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes : Focus on dipeptidyl peptidase-4 inhibition
(
- Contribution to journal › Scientific review
- 2020
-
Mark
The incretin effect in female mice with double deletion of GLP-1 and GIP receptors
(
- Contribution to journal › Article
-
Mark
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
(
- Contribution to journal › Article
- 2019
-
Mark
Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development
(
- Contribution to journal › Article
-
Mark
Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
(
- Contribution to journal › Article
-
Mark
Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice
2019) In American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 316(1). p.27-37(
- Contribution to journal › Article
-
Mark
Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects.
(
- Contribution to journal › Article
-
Mark
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).
(
- Contribution to journal › Article
-
Mark
Reductioninglycatedhemoglobin and daily insulin dose alongside circadian clock upregulation in patients with type 2 diabetes consuming a three-meal diet : A randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
(
- Contribution to journal › Article
-
Mark
Islet adaptation in GIP receptor knockout mice
2019) In Peptides(
- Contribution to journal › Scientific review
-
Mark
DPP-4 inhibition and the path to clinical proof
(
- Contribution to journal › Article
- 2018
-
Mark
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes : A randomized, placebo-controlled study
(
- Contribution to journal › Article
-
Mark
Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors
2018) In American Journal of Physiology - Regulatory Integrative and Comparative Physiology 314(5). p.639-646(
- Contribution to journal › Article
-
Mark
Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects
(
- Contribution to journal › Article
-
Mark
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
(
- Contribution to journal › Article
-
Mark
DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
(
- Contribution to journal › Article
-
Mark
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
(
- Contribution to journal › Article
- 2017
-
Mark
The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2) : a 56-week, double-blind, phase 3a, randomised trial
(
- Contribution to journal › Article
-
Mark
High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Albiglutide for the treatment of type 2 diabetes mellitus : An integrated safety analysis of the HARMONY phase 3 trials
(
- Contribution to journal › Article
-
Mark
Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice
(
- Contribution to journal › Article
-
Mark
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus : Results over 52 weeks
(
- Contribution to journal › Article
-
Mark
Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes : A randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring
(
- Contribution to journal › Article
-
Mark
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus : Long-term efficacy with or without rescue therapy
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide : effects alone and in combination on insulin secretion and glucose disappearance in mice
(
- Contribution to journal › Article
-
Mark
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes : A randomized, open-label, 2-arm parallel comparative, exploratory trial
(
- Contribution to journal › Article
-
Mark
Alain Ktorza, PhD
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
Mixed meal diminishes glucose excursion compared to glucose by several adaptive mechanisms in man.
(
- Contribution to journal › Article
-
Mark
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
2016) In Diabetologia(
- Contribution to journal › Article
-
Mark
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
(
- Contribution to journal › Article
-
Mark
Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
(
- Contribution to journal › Article
-
Mark
Enhanced Insulin Sensitivity by Adipose Tissue Browning Alters Islet Morphology and Hormone Secretion in Response to Autonomic Nervous Activation in Female Mice.
(
- Contribution to journal › Article
-
Mark
Decreased insulin secretion and glucose clearance in exocrine pancreas-insufficient pigs.
(
- Contribution to journal › Article
-
Mark
Evidence for time dependent variation of glucagon secretion in mice.
(
- Contribution to journal › Article
-
Mark
Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.
(
- Contribution to journal › Article
-
Mark
Incretin hormone receptors are required for normal beta cell development and function in female mice
(
- Contribution to journal › Article
-
Mark
Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes
(
- Contribution to journal › Article
-
Mark
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis
(
- Contribution to journal › Article
-
Mark
Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation
(
- Contribution to journal › Article
-
Mark
Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
(
- Contribution to journal › Article
-
Mark
CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes : The adjunct two randomized trial
(
- Contribution to journal › Article
-
Mark
Evidence for neural contribution to islet effects of DPP-4 inhibition in mice
(
- Contribution to journal › Article
-
Mark
Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition
(
- Contribution to journal › Scientific review
- 2015
-
Mark
High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial
(
- Contribution to journal › Article
-
Mark
Incretin and islet hormone responses to meals of increasing size in healthy subjects.
(
- Contribution to journal › Article
-
Mark
The Islet and Metabolism Keep Time
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice.
(
- Contribution to journal › Article
-
Mark
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.
(
- Contribution to journal › Article
-
Mark
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
(
- Contribution to journal › Article
-
Mark
Deciphering the hypoglycemic glucagon response: development of a graded hyperinsulinemic hypoglycemic clamp technique in female mice.
(
- Contribution to journal › Article
-
Mark
DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
(
- Contribution to journal › Article
-
Mark
Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes.
(
- Contribution to journal › Article
-
Mark
Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Are there not some surrogate indexes lost in this story? Reply to Bastard JP, Rabasa-Lhoret R, Laville M and Disse E [letter]
(
- Contribution to journal › Letter
-
Mark
Glucagon-early breakthroughs and recent discoveries.
(
- Contribution to journal › Scientific review
-
Mark
Incretin Effect after Oral Amino Acid Ingestion in Humans.
(
- Contribution to journal › Article
-
Mark
Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.
(
- Contribution to journal › Article
-
Mark
Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial.
(
- Contribution to journal › Article
-
Mark
Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.
(
- Contribution to journal › Article
-
Mark
Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes.
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
The neuro-incretin concept.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis
(
- Contribution to journal › Article
-
Mark
Pronounced Reduction Of Postprandial Glucagon By Lixisenatide: A Meta-Analysis Of Randomized Clinical Trials.
(
- Contribution to journal › Article
-
Mark
Fibroblast Growth Factor 21 (FGF21) and Glucagon Like-Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor Deficient Mice.
(
- Contribution to journal › Article
-
Mark
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
(
- Contribution to journal › Article
-
Mark
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
(
- Contribution to journal › Article
-
Mark
Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function.
(
- Contribution to journal › Article
-
Mark
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
(
- Contribution to journal › Article
-
Mark
The mind and the belly: a glance at how the nervous system directs metabolism
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial
(
- Contribution to journal › Article
-
Mark
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.
(
- Contribution to journal › Article
-
Mark
Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
(
- Contribution to journal › Article
-
Mark
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin.
(
- Contribution to journal › Article
-
Mark
Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors.
(
- Contribution to journal › Article
-
Mark
Impact of glucose dosing regimens on modeling of glucose tolerance and β-cell function by intravenous glucose tolerance test in diet-induced obese mice.
(
- Contribution to journal › Article
-
Mark
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders(
- Contribution to journal › Article
-
Mark
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
(
- Contribution to journal › Scientific review
-
Mark
Glucagon clearance is regulated by nutritional state : Evidence from experimental studies in mice
(
- Contribution to journal › Article
-
Mark
Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets.
(
- Contribution to journal › Article